Vĕtr M, Talas M, Pohanka J, Gazárek F, Fingerová H
Medical Faculty, Palacký University, Olomouc, Czechoslovakia.
Acta Univ Palacki Olomuc Fac Med. 1990;125:155-60.
Thirty-two women with ovarian dysfunction due to hyperprolactinemia were treated with a new derivative of lisuride-terguride. Twenty-three patients were treated for infertility. A microadenoma was confirmed in five, and three other patients had had a macroprolactinoma surgically removed. The finding in one of the patients was diagnosed as the syndrome of empty sella. Galactorrhea was present in 18 women. The duration of treatment ranged from 2 to 33 months. The determination of therapeutic dosages was based on individual responses on the prolactin levels within a range from 0.1 to 4.5 mg per day. Increased prolactin levels were successfully normalized in twenty-one treated patients. Regular periods were reappeared in 59% of the women. Thirteen (56%) became pregnant, seven gave birth to healthy babies, two of the patients aborted in the first trimester. Four women are still in later stages of pregnancy. Galactorrhea disappeared in 56% of the patients, being markedly inhibited in the remaining ones. In two cases, microadenoma disappeared after treatment, and in those after surgery the postoperative findings were decreased, in one patients there is no alteration in the pathology. Side effects were seen in 34% of the patients, being mostly mild in nature, and including in most cases nausea, headache and stomach pain. The complaints were transient, receding after prolonged treatment.
32名因高催乳素血症导致卵巢功能障碍的女性接受了一种新型利舒脲衍生物——特古瑞肽的治疗。23名患者因不孕症接受治疗。5名患者确诊为微腺瘤，另外3名患者已通过手术切除大催乳素瘤。1名患者的检查结果被诊断为空蝶鞍综合征。18名女性存在溢乳现象。治疗持续时间为2至33个月。治疗剂量的确定基于个体对催乳素水平的反应，范围为每天0.1至4.5毫克。21名接受治疗的患者催乳素水平升高成功恢复正常。59%的女性月经恢复正常。13名（56%）患者怀孕，7名顺利产下健康婴儿，2名患者在孕早期流产。4名女性仍处于妊娠晚期。56%的患者溢乳消失，其余患者溢乳明显受到抑制。2例患者治疗后微腺瘤消失，接受手术的患者术后检查结果有所减轻，1例患者病理无变化。34%的患者出现副作用，大多性质轻微，多数情况下包括恶心、头痛和胃痛。这些不适是短暂的，经过长时间治疗后消退。
